511 filings
Page 5 of 26
8-K
6irxs1ibx3w 45bn
16 Mar 21
CORPORATE PRESENTATION March 2021
5:16pm
424B5
444khhy3q6z1c478h
15 Mar 21
Prospectus supplement for primary offering
4:30pm
424B5
quu hre00
11 Mar 21
Prospectus supplement for primary offering
4:06pm
8-K
7esvx p17r
9 Mar 21
Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results
4:36pm
8-K
78grg46
3 Mar 21
Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant
7:41am
8-K
1orz zvd7kked
13 Jan 21
Regulation FD Disclosure
7:43am
8-K
d22igv 4vwse55fo2h8
5 Jan 21
Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial
4:01pm
8-K
ts8hf0 j5lv
9 Nov 20
Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results
4:18pm
8-K
3r6wr5dds43ve
10 Aug 20
Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results
4:29pm
8-K
fa4s2bndi03d
30 Jun 20
Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates
9:13am
8-K
2yys5v4
23 Jun 20
Regulation FD Disclosure
8:51am
S-8
bunn7
12 Jun 20
Registration of securities for employees
4:16pm
8-K
e2u114lbvu7clon8p6
1 Jun 20
Regulation FD Disclosure
9:22am
8-K
qu2k4ueb3z
29 May 20
Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical
8:17am
8-K
qhx5 afyi6wow
21 May 20
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
p75 lgfkfs566otc3mrj
11 May 20
Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results
4:17pm